tiprankstipranks
Advertisement
Advertisement
Incyte: Halozyme Collaboration Improves INCA033989 Delivery but Dose Requirements Keep Rating at Hold
PremiumRatingsIncyte: Halozyme Collaboration Improves INCA033989 Delivery but Dose Requirements Keep Rating at Hold
6d ago
Incyte: ENHANZE Licensing Bolsters INCA033989 Outlook as Buy Rating and $140 Price Target Are Reiterated
Premium
Ratings
Incyte: ENHANZE Licensing Bolsters INCA033989 Outlook as Buy Rating and $140 Price Target Are Reiterated
6d ago
Halozyme announces global collaboration, license agreement with Incyte
Premium
The Fly
Halozyme announces global collaboration, license agreement with Incyte
7d ago
Incyte completes acquisition of Vega Therapeutics
PremiumThe FlyIncyte completes acquisition of Vega Therapeutics
21d ago
Citizens biotech analysts hold an analyst/industry conference call
Premium
The Fly
Citizens biotech analysts hold an analyst/industry conference call
25d ago
Buy Rating Reaffirmed as Opzelura’s Global Opportunity Expands and DCF-Supported $140 Price Target Is Maintained
Premium
Ratings
Buy Rating Reaffirmed as Opzelura’s Global Opportunity Expands and DCF-Supported $140 Price Target Is Maintained
28d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100